Several FMD trials have been initiated, including an FMD-ICI trial examining a 4-day FMD in advanced cancer patients on anti-PD-1/PD-L1 or anti-CTLA4 ICIs, alone or in combination (NCT06438588), and NCT06671613 for plant-based FMD in patients with metastatic NSCLC undergoing pembrolizumab treatment. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.